NUVL News and Press, Nuvalent Inc.

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 PR Newswire CAMBRIDGE, Mass. , March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical compa...

2026-03-16 20:20:55 ET On February 17, 2026, Vestal Point Capital disclosed in a Securities and Exchange Commission (SEC) filing that it sold 1,054,000 shares of Nuvalent (NASDAQ:NUVL) , an estimated $103.93 million transaction based on quarterly average pricing. According to a ...

2026-02-26 06:43:07 ET More on Nuvalent Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent Financial information for Nuvalent ...

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-pos...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-23 10:21:48 ET Commodore Capital reported a sale of 850,000 shares of Nuvalent (NASDAQ:NUVL) in its latest SEC filing dated February 17, 2026, with the estimated transaction value at $83.81 million based on quarterly average pricing. According to a Securities and Excha...

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PR Newswire CAMBRIDGE, Mass. , Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clini...

2026-01-13 15:26:00 ET Nuvalent, Inc. (NUVL) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones PR Newswire FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 ...

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted thera...